Company intelligence / Profile preview

LASSO

San Diego, California, United Stateslassomusica.com ↗

Ownership: Private
Development stage: Commercial

Overview

Lassogen has demonstrated the ability to engineer highly stable, selective lasso peptides that modulate difficult drug targets such as GPCRs. Their lead candidate LAS‑103 selectively antagonizes the endothelin type B receptor to enhance immune infiltration into tumors. The company’s technology enables rapid discovery and optimization of novel macrocyclic peptides from a vast natural sequence space.

Therapeutic areas: OncologyImmunologyOther
Modalities: Lasso peptideLassotides™Peptide (macrocyclic peptide)Biologic
Industry: Biotech

Partnerships

Playground Global (investment partnership)University of Illinois Urbana-Champaign (academic collaboration)University of California San Diego (academic collaboration)

Beyond the preview

Go deeper on LASSO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LASSO.

Explore the full profile